We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+13.9%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$366M
AUM Growth
+$32.2M
Cap. Flow
+$2.36M
Cap. Flow %
0.64%
Top 10 Hldgs %
49.41%
Holding
80
New
7
Increased
18
Reduced
15
Closed
7

Top Buys

Rank Stock Value
1
DAWN
Day One Biopharmaceuticals
DAWN
+$6.62M
2
TSVT
2seventy bio
TSVT
+$5.26M
3
TNDM icon
Tandem Diabetes Care
TNDM
+$3.54M
4
KURA icon
Kura Oncology
KURA
+$2.93M
5
MRUS
Merus
MRUS
+$2.21M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$7.8M
2
CSII
Cardiovascular Systems, Inc.
CSII
+$5.7M
3
APLS
Apellis Pharmaceuticals
APLS
+$3.81M
4
BHVN icon
Biohaven
BHVN
+$3.69M
5
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$2.07M

Sector Composition

Rank Sector Weight
1 Healthcare 82.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATXS
51
DELISTED
Astria Therapeutics
ATXS
$1.06M 0.29%
127,653
+57,770
+83% +$667K
ACRV icon
52
Acrivon Therapeutics
ACRV
$66.8M
$996K 0.27%
76,852
+25,704
+50% +$311K
SURF
53
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$957K 0.26%
1,100,000
– –
SYRS
54
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$838K 0.23%
265,878
– –
PRDS
55
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$779K 0.21%
430,291
-49,095
-10% -$89.8K
NVRO
56
DELISTED
NEVRO CORP.
NVRO
$712K 0.19%
+28,000
New +$808K
ELEV
57
DELISTED
Elevation Oncology
ELEV
$684K 0.19%
+450,000
New +$1.19M
STIM icon
58
Neuronetics
STIM
$156M
$674K 0.18%
313,717
– –
SPRB
59
Spruce Biosciences
SPRB
$122M
$671K 0.18%
4,160
– –
BHVN icon
60
Biohaven
BHVN
$2.04B
$505K 0.14%
21,113
-214,500
-91% -$3.69M
MASI
61
DELISTED
Masimo
MASI
$494K 0.14%
3,000
– –
CMPX icon
62
Compass Therapeutics
CMPX
$353M
$372K 0.1%
116,882
– –
KPTI icon
63
Karyopharm Therapeutics
KPTI
$46.2M
$345K 0.09%
12,845
– –
NXTC icon
64
NextCure
NXTC
$23M
$338K 0.09%
15,641
– –
ADAP
65
DELISTED
Adaptimmune Therapeutics
ADAP
$325K 0.09%
351,064
– –
MDNA
66
DELISTED
Medicenna Therapeutics Corp. Common Shares
MDNA
$318K 0.09%
660,000
– –
PRCT icon
67
Procept Biorobotics
PRCT
$1.03B
$283K 0.08%
+8,000
New +$265K
KNTE
68
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$243K 0.07%
80,179
-829
-1% -$3.2K
CGEN icon
69
Compugen
CGEN
$220M
$234K 0.06%
205,202
– –
LCTX icon
70
Lineage Cell Therapeutics
LCTX
$284M
$197K 0.05%
140,000
– –
SPRO icon
71
Spero Therapeutics
SPRO
$69.5M
$181K 0.05%
125,000
– –
INGN icon
72
Inogen
INGN
$185M
$173K 0.05%
15,000
– –
APLS
73
DELISTED
Apellis Pharmaceuticals
APLS
– –
-57,746
Closed -$3.81M
GNFT
74
DELISTED
Genfit
GNFT
– –
-197,940
Closed -$812K
IMA
75
ImageneBio Inc
IMA
$65.3M
– –
-9,411
Closed -$390K
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return

DAFNA Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, DAFNA Capital Management held 80 positions worth $366M, up 9.7% from $334M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

DAFNA Capital Management's Q2 2023 filing shows 7 new, 18 increased, 15 reduced and 7 closed positions. Its largest new stake was Day One Biopharmaceuticals: 507,100 shares worth $6.05M. The largest sale was Karuna Therapeutics, Inc. Common Stock, an estimated $7.8M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 81% a quarter earlier.

  • DAFNA Capital Management's largest Q2 2023 buy was Day One Biopharmaceuticals: 507,100 shares worth $6.05M.
  • DAFNA Capital Management added most to Kura Oncology in Q2 2023, an estimated $2.93M increase.
  • DAFNA Capital Management's biggest Q2 2023 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $7.8M.
  • DAFNA Capital Management fully exited Cardiovascular Systems, Inc. in Q2 2023, selling an estimated $5.7M.
  • DAFNA Capital Management's ten largest holdings make up 49% of its $366M portfolio in Q2 2023.
  • DAFNA Capital Management opened 7 new positions and closed 7 in Q2 2023.
  • DAFNA Capital Management's portfolio value rose 9.7% quarter-over-quarter to $366M.

Based on DAFNA Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.